9. SOPHiA GENETICS SA (NASDAQ:SOPH)
SOPHiA GENETICS SA (NASDAQ: SOPH) takes ninth place as one of the most AI-focused precision medicine companies in the public market.
The company operates a cloud-based platform that analyzes genomic and multimodal healthcare information. Hospitals, clinical laboratories and pharmaceutical companies use the platform to interpret complex medical data, identify genetic characteristics and support more personalized treatment decisions.
This is an area in which artificial intelligence can provide practical value. Modern sequencing systems can generate enormous amounts of genomic data, but producing the data is only the beginning. Healthcare institutions still need software that can analyze the information and convert it into clinically useful insights.
Second-quarter 2026 revenue increased 27% year over year to approximately $23.3 million. Analysis volume climbed 22% to a quarterly record of around 115,000, while the company signed 24 new customers.
Growth was especially strong in important expansion markets. U.S. revenue increased 64%, while liquid-biopsy revenue jumped 80%. The company also reported 993 customers across 75 countries, including relationships with several leading global cancer centers.
Its recurring, volume-based business model is another positive. Annualized revenue churn remained below 1%, while net dollar retention reached 117%. Those figures suggest that existing customers are not only staying on the platform but are also expanding their usage.
The financial picture is less convincing. The company remains unprofitable and reported an adjusted EBITDA loss of approximately $8.8 million during the second quarter. That was an improvement from a $12 million loss one year earlier, but the path toward sustainable profitability remains unfinished.
SOPHiA GENETICS SA (NASDAQ: SOPH) deserves attention because artificial intelligence is not simply a marketing label attached to an unrelated healthcare operation. AI has been central to the platform since its founding. Nevertheless, its relatively small revenue base and continuing losses make it one of the riskier AI healthcare stocks in this ranking.
